Barriers to access to hepatitis C treatment

Journal of Infection in Developing Countries

Volumn 10, Issue 4, 2016, Pages 308-316

  Yilmaz, Hava ^a   Yilmaz, Esmeray Mutlu ^b   Leblebicioglu, Hakan ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Anti HCV; Antiviral drugs; Hepatitis C; Treatment; Viral load

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HEPATITIS C VACCINE; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; COST; DISEASE ELIMINATION; DRUG MARKETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FINANCIAL MANAGEMENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; LOWEST INCOME GROUP; POLYMERASE CHAIN REACTION; PUBLIC HEALTH SERVICE; REVIEW; SEROPREVALENCE; VACCINATION; VIRUS LOAD; WORLD HEALTH ORGANIZATION; HEALTH CARE DELIVERY; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS;

EID: 84964739521     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.7849     Document Type: Review

References (34)

1. Lemoine M, Nayagam S, Thursz M (2013) Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 8: 371-380.
2. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW (2013) A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 57: 1325-1332.
3. Okeke IN, Lamikanra A, Edelman R (1999) Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 5: 18-27.
4. Sirinavin S, Dowell SF (2004) Antimicrobial resistance in countries with limited resources: unique challenges and limited alternatives. Semin Pediatr Infect Dis 15: 94-98.
5. Maheshwari A, Ray S, Thuluvath PJ (2008) Acute hepatitis C. Lancet 26: 321-332.
6. Hill A, Khoo S, Fortunak J, Simmons B, Ford N (2014) Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 58: 928-936.
7. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ (2014) Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 21 Suppl 1: 5-33.
8. Sharvadze L, Nelson KE, Imnadze P, Karchava M, Tsertsvadze T (2008) Prevalence of HCV and genotypes distribution in general population of Georgia. Georgian Med News 165: 71-77.
9. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle PY, Fontanet A; HCV epidemiology in Africa group (2016) Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat 23: 244-55.
10. Wedemeyer H, Dore GJ, Ward JW (2015) Estimates on HCV disease burden worldwide-filling the gaps. J Viral Hepat 22 Suppl 1: 1-5.
11. Lemoine M, Thursz M (2014) Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis 34: 89-97.
12. Marwaha N, Sachdev S (2014) Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol 20: 2948-2954.
13. Dodd RY, Notari EP 4th, Stramer SL (2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42: 975-979.
14. van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A (2015) Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 61: 1174-1182.
15. World Health Organization (WHO) (2014) Guidelines for the screening, care and treatment of persons with hepatitis C infection. Available: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf. Accessed 20 June 2015.
16. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, du Cros P (2012) Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 54: 1465-1472.
17. Kaplan K, Treatment Action Group (2015) Activist strategies for increasing access to HCV treatment in low- and middle-income countries. Available: http://www.treatmentactiongroup.org/sites/g/files/g450272/f/201502/Activist%20Strategies%20for%20HCV%20Tx.pdf. Accessed 20 June 2015.
18. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578.
19. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH (2015) From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62 Suppl 1: 87-99.
20. Laupland KB, Valiquette L (2015) The dollars and sense of chronic hepatitis C infection management. Can Infect Dis Med Microbiol 26: 119-121.
21. Lok ASF (2014) New all-oral HCV therapies for Genotype 1: a final good-bye to interferon. Clin Liver Dis 3: 137-140.
22. HepCoalition. Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: A Fool’s Bargain. Myths and Facts. Available: http://www.hepcoalition.org/news/article/gilead-s-license-on-hepatitis-c. Accessed 20 June 2015.
23. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW (2015) The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 61: 157-168.
24. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, Celentano DD, Iqbal SH, Anand S, Vasudevan CK, Saravanan S, Lucas GM, Kumar MS, Sulkowski MS, Quinn TC (2015) Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis 15: 36-45.
25. Ocheret D, Bikmukhametov D, Sultangaziev A, Matuizaite E (2013) Current situation regarding access to hepatitis C treatment in Eastern Europe and Central Asia. Available: http://www.harm-reduction.org/sites/default/files/pdf/hep_c_policy_brief_update_en_edited_3.pdf. Accessed 29 June 2015.
26. Ghany MG, Liang TJ (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 369: 679-680.
27. Brennan T, Shrank W (2014) New expensive treatments for hepatitis C infection. JAMA 312: 593-594.
28. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M (2014) Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 28: 243-250.
29. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM (2002) Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36: 211-228.
30. Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, Abdel-Hamid M, Doss W, Esmat G, Mohamed MK, Fontanet A (2014) Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Glob Health 2: e541-e549.
31. Hauri AM, Armstrong GL, Hutin YJ (2004) The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 15: 7-16.
32. Stvilia K, Tsertsvadze T, Sharvadze L, Aladashvili M, del Rio C, Kuniholm H, Nelson KE (2006) Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia. J Urban Health 83: 289-298.
33. Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, Chokheli M, Drobeniuc J, Hagan L, Harris AM, Jiqia T, Kasradze A, Ko S, Qerashvili V, Sharvadze L, Tskhomelidze I, Kvaratskhelia V, Morgan J, Ward JW, Averhoff F (2015) Launch of a nationwide hepatitis C elimination program--Georgia, April 2015. Morb Mortal Wkly Rep 64: 753-757.
34. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle PY, Fontanet A; HCV epidemiology in Africa group (2016) Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat 23: 244-55.